Clinical trials: Influenza Immunization
Influenza Vaccines Efficacy and Safety
Efficacy & Safety of Nasal Influenza Immunisation in Children
The UK Departments of Health now recommend annual influenza vaccination for all children 2-7 years of age, with children over 7 years eligible for vaccination if in certain higher risk clinical categories.
- Trial name
- SNIFFLE-3 (NCT02549365)
- Testing
- Live attenuated influenza vaccine, Surveillance (nasal swabbing) during influenza season
- Where
- United Kingdom
- Volunteers
- 276 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Influenza, Influenza Immunisation
Development of Childhood Anti-Influenza Immunity
This study is a prospective surveillance of the immune response to seasonal vaccination in healthy children. The study will enroll a total of approximately 220 subjects.
- Trial name
- NCT03673345
- Testing
- Influenza Virus Quadrivalent Inactivated Vaccine
- Where
- United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza Vaccination
PROmotion of FLU Vaccine Uptake in the Emergency Department - PROFLUVAXED
The goal of this research is to increase influenza vaccine acceptance and uptake in vulnerable populations whose primary (and often only) health care access occurs in emergency departments (ED Usual Source of Care Patients).
- Trial name
- PROFLUVAXED (NCT05836818)
- Testing
- Question (Q), Messaging (M)
- Where
- 8 sites in United States
- Volunteers
- 776 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Avian Influenza, Influenza Immunisation
Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly
This is a randomized, double-blinded, Phase II study in healthy males and non-pregnant females 19 years and older that is designed to assess the safety, reactogenicity, and immunogenicity of a pre-pandemic 2017 monovalent…
- Trial name
- NCT03312231
- Testing
- AS03, Inactivated influenza H7N9 vaccine, Phosphate Buffered Saline (PBS) diluent
- Where
- 5 sites in United States
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 Years
The purpose of this Phase 3, observer-blind, placebo-controlled, multi-center study is to characterize the immunogenicity \& safety of the investigation vaccination regimen of GSK 1557484A vaccine given to adults aged ≥18 years.
- Trial name
- NCT00616928
- Testing
- Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted
- Where
- 40 sites in United States, Canada
- Volunteers
- 4,561 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Vaccination
Flu2Text: Text Message Reminders for 2nd Dose of Influenza Vaccine
This multi-site study assesses the impact of text message reminders on the receipt of the second dose of influenza vaccine, and takes place primarily in practices from the American Academy of Pediatrics (AAP) Pediatric Research…
- Trial name
- F2T (NCT03287830)
- Testing
- Text message influenza vaccine reminders
- Where
- 3 sites in United States
- Volunteers
- 2,105 people
- Sponsor
- Columbia University
Influenza
Nudging Flu Vaccination by Making it Easy for Patients to Schedule a Flu Shot
The purpose of this study is to test whether messages that make it easy to schedule a flu shot appointment will increase flu shot rates in patients without an upcoming appointment.
- Trial name
- NCT05493787
- Testing
- Reminder
- Where
- United States
- Volunteers
- 139,503 people
- Sponsor
- Geisinger Clinic
Influenza
From Innovation to Solutions: Childhood Influenza Vaccination Planning
The purpose of this study is to increase childhood influenza vaccination rates using the FDA licensed influenza vaccines according to national guidelines in a randomized cluster trial in which primary care offices are randomized…
- Trial name
- NCT01664793
- Testing
- 4 Pillars Immunization Toolkit
- Where
- United States
- Volunteers
- 87,665 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Pregnancy
PregText: Feasibility of Monitoring Influenza Vaccine Safety in Pregnant Women Using Text Messaging
In this study, the investigators will prospectively assess fever rates and other adverse events in pregnant women after administration of inactivated influenza vaccine (IIV) using text messaging.
- Trial name
- NCT01974050
- Testing
- Text message surveillance
- Where
- United States
- Volunteers
- 166 people
- Sponsor
- Columbia University
Immunization; Infection, Pregnancy Related
Increasing Influenza and Tdap Vaccination of Pregnant Women
Pregnant women who get influenza are more likely than non-pregnant women to have serious complications, including hospitalizations, death, preterm labor and premature birth.
- Trial name
- NCT04444518
- Testing
- VAX-MOM Intervention, Standard of Care
- Where
- United States
- Volunteers
- 12,760 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Healthy
Entolimod on Immunosenescence in Healthy Geriatric Subjects Receiving Influenza Vaccination
Researchers are evaluating the safety and effectiveness of a single administration of entolimod when administered at the same time as the influenza vaccine (flu vaccine).
- Trial name
- NCT04176133
- Testing
- Entolimod, Influenza vaccine
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Robert J. Pignolo
Influenza Immunization
Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.
The purpose of this study was to demonstrate the non-inferiority (NI) of the HAI immune response of RIV4 in participants aged 9 to 17 years vs participants aged 18 to 49 years and to describe the immunogenicity and safety profile…
- Trial name
- NCT05513053
- Testing
- Quadrivalent Recombinant influenza vaccine (RIV4) season/2022-2023/NH
- Where
- 35 sites in United States, Czechia and 2 more
- Volunteers
- 1,308 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Immune Response Following Seasonal Influenza Vaccination
This is an open-label, single administration dose study in adult healthy male and female subjects. After qualifying for the study, subjects will receive a single intramuscular injection of the FDA approved 2016-2017 quadrivalent…
- Trial name
- NCT03163342
- Testing
- Licensed seasonal influenza vaccine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Altimmune, Inc.
Influenza
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
This study is to evaluate the safety, tolerability and immune response when 13-valent pneumococcal conjugate vaccine (13vPnC) and the trivalent inactivated flu vaccine (TIV) are given together to healthy adults aged 50-59 years…
- Trial name
- NCT00521586
- Testing
- 13 valent pneumococcal conjugate vaccine
- Where
- 41 sites in United States
- Volunteers
- 1,116 people, healthy volunteers welcome
- Sponsor
- Pfizer
Avian Influenza, Influenza Immunisation
2017 A/H7N9 IIV Revaccination
This is a Phase II clinical trial in up to 420 males and non-pregnant females, 19 to 70 years of age, inclusive, who are in good health and meet all eligibility criteria.
- Trial name
- NCT03738241
- Testing
- A/H7N9, AS03, Phosphate Buffered Saline (PBS) diluent
- Where
- 9 sites in United States
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)